StageZero Life Sciences Ltd.
StageZero Life Sciences Ltd.
Your view on SZLSF
Overview
What the company does, where it operates, and who runs it.
About StageZero Life Sciences Ltd.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- James R. Howard-Tripp
- Headquarters
- 70 East Beaver Creek Road, Richmond Hill, ON, CA
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- James R. Howard-Tripp
- Headquarters
- 70 East Beaver Creek Road, Richmond Hill, ON, CA
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada.
Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer.
It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer.
The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for StageZero Life Sciences Ltd., and the rating behind it. SZLSF last traded at $0.0005; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for StageZero Life Sciences Ltd.. Starting points for StageZero Life Sciences Ltd.: EPS -$0.11, beta 0.34 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for StageZero Life Sciences Ltd.. StageZero Life Sciences Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for StageZero Life Sciences Ltd.. Trailing twelve-month EPS for StageZero Life Sciences Ltd. stands at -$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for StageZero Life Sciences Ltd.. StageZero Life Sciences Ltd. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
StageZero Life Sciences Ltd. valued side by side against its closest peers. StageZero Life Sciences Ltd. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold StageZero Life Sciences Ltd., and how their positions are changing. At a $61,766 market value, institutional positions materially move StageZero Life Sciences Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by StageZero Life Sciences Ltd. executives and directors. Shares of StageZero Life Sciences Ltd. have traded between $0.0005 and $0.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming StageZero Life Sciences Ltd.. StageZero Life Sciences Ltd. is a $61,766 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming StageZero Life Sciences Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for StageZero Life Sciences Ltd.. Coverage tracks StageZero Life Sciences Ltd. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.